Journal of Autoimmunity

Papers
(The H4-Index of Journal of Autoimmunity is 42. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
The 2022 outbreak and the pathobiology of the monkeypox virus320
Autoinflammatory and autoimmune conditions at the crossroad of COVID-19230
Evolutionary analysis of the Delta and Delta Plus variants of the SARS-CoV-2 viruses210
Omicron SARS-CoV-2 variant: Unique features and their impact on pre-existing antibodies178
Complement activation and endothelial perturbation parallel COVID-19 severity and activity127
Mechanisms of Immunothrombosis in Vaccine-Induced Thrombotic Thrombocytopenia (VITT) Compared to Natural SARS-CoV-2 Infection123
Mitigating Covid-19 in the face of emerging virus variants, breakthrough infections and vaccine hesitancy106
Ferritin – from iron, through inflammation and autoimmunity, to COVID-19102
COVID-19 convalescent plasma composition and immunological effects in severe patients95
Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients’ subgroups91
Autoimmune hepatitis triggered by SARS-CoV-2 vaccination89
Acute autoimmune-like hepatitis with atypical anti-mitochondrial antibody after mRNA COVID-19 vaccination: A novel clinical entity?78
Autoimmune hepatitis after COVID-19 vaccine – more than a coincidence75
Auto-immune hepatitis following COVID vaccination72
The JANUS of chronic inflammatory and autoimmune diseases onset during COVID-19 – A systematic review of the literature69
Safety and efficacy of fecal microbiota transplantation for treatment of systemic lupus erythematosus: An EXPLORER trial68
Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients68
Abnormalities of T cells in systemic lupus erythematosus: new insights in pathogenesis and therapeutic strategies67
A case of Graves' disease and type 1 diabetes mellitus following SARS-CoV-2 vaccination67
Autoantibodies against ACE2 and angiotensin type-1 receptors increase severity of COVID-1959
Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case reports and updated literature review58
Lupus nephritis: new progress in diagnosis and treatment58
Autoimmune hepatitis after SARS-CoV-2 vaccine: New-onset or flare-up?57
Marginal zone B cells: From housekeeping function to autoimmunity?55
Resistant starch intake alleviates collagen-induced arthritis in mice by modulating gut microbiota and promoting concomitant propionate production55
Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab53
Blood clots and bleeding events following BNT162b2 and ChAdOx1 nCoV-19 vaccine: An analysis of European data52
Cardiovascular disease risk in antiphospholipid syndrome: Thrombo-inflammation and atherothrombosis51
A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases48
Perspectives on vaccine induced thrombotic thrombocytopenia47
Cardiovascular, neurological, and pulmonary events following vaccination with the BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: An analysis of European data47
Autoantibodies in systemic lupus erythematosus: From immunopathology to therapeutic target47
Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development47
The complement system and human autoimmune diseases47
New developments implicating IL-21 in autoimmune disease46
Regulatory T cells in autoimmune hepatitis: an updated overview46
Mushrooms and immunity45
Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study44
Chromosome 3 cluster rs11385942 variant links complement activation with severe COVID-1944
Guideline for the diagnosis, treatment and long-term management of cutaneous lupus erythematosus43
Coronavirus disease 2019, immune-mediated inflammatory diseases and immunosuppressive therapies – A Danish population-based cohort study42
High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients42
Extracellular vesicles and lupus nephritis - New insights into pathophysiology and clinical implications42
0.05402398109436